Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 105.40M | 127.50M | 99.22M | 81.50M | 63.85M |
| Total Other Revenue | -- | 2.00M | -- | -- | 2.00M |
| Total Revenue | 105.40M | 129.50M | 99.22M | 81.50M | 65.85M |
| Cost of Revenue | 9.78M | 11.69M | 8.69M | 7.49M | 8.83M |
| Gross Profit | 95.61M | 117.82M | 90.53M | 74.01M | 57.02M |
| SG&A Expenses | 74.08M | 78.98M | 62.40M | 69.17M | 64.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.49M | 111.12M | 90.69M | 96.12M | 90.38M |
| Operating Income | -9.09M | 18.39M | 8.53M | -14.61M | -24.53M |
| Income Before Tax | -11.20M | 17.87M | 7.49M | -15.54M | -24.78M |
| Income Tax Expenses | 93.00K | 470.00K | 80.00K | 342.00K | 279.00K |
| Earnings from Continuing Operations | -11.30M | 17.40M | 7.41M | -15.89M | -25.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.30M | 17.40M | 7.41M | -15.89M | -25.06M |
| EBIT | -9.09M | 18.39M | 8.53M | -14.61M | -24.53M |
| EBITDA | -8.53M | 18.95M | 9.09M | -14.20M | -21.55M |
| EPS Basic | -0.09 | 0.14 | 0.06 | -0.13 | -0.20 |
| Normalized Basic EPS | -0.05 | 0.09 | 0.04 | -0.08 | -0.12 |
| EPS Diluted | -0.09 | 0.12 | 0.06 | -0.13 | -0.20 |
| Normalized Diluted EPS | -0.05 | 0.08 | 0.04 | -0.08 | -0.12 |
| Average Basic Shares Outstanding | 129.37M | 128.25M | 127.62M | 127.00M | 126.04M |
| Average Diluted Shares Outstanding | 129.37M | 135.64M | 132.88M | 127.00M | 126.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |